Catalyst Capital Advisors LLC Invests $1.11 Million in Neurocrine Biosciences, Inc. $NBIX

Catalyst Capital Advisors LLC bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 7,800 shares of the company’s stock, valued at approximately $1,106,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. AlTi Global Inc. lifted its position in shares of Neurocrine Biosciences by 1.0% in the 3rd quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock worth $959,000 after purchasing an additional 70 shares during the period. Huntington National Bank lifted its position in shares of Neurocrine Biosciences by 12.6% in the 4th quarter. Huntington National Bank now owns 678 shares of the company’s stock worth $96,000 after purchasing an additional 76 shares during the period. Vanguard Personalized Indexing Management LLC lifted its position in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock worth $1,560,000 after purchasing an additional 77 shares during the period. Perigon Wealth Management LLC lifted its position in shares of Neurocrine Biosciences by 3.1% in the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock worth $367,000 after purchasing an additional 78 shares during the period. Finally, Signaturefd LLC lifted its position in shares of Neurocrine Biosciences by 4.5% in the 4th quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock worth $273,000 after purchasing an additional 83 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $158.30 on Friday. The firm’s 50 day moving average price is $139.36 and its 200-day moving average price is $139.16. The company has a market cap of $15.92 billion, a PE ratio of 24.39, a P/E/G ratio of 1.17 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 52-week low of $121.42 and a 52-week high of $162.39.

Wall Street Analysts Forecast Growth

NBIX has been the subject of several research analyst reports. Wedbush raised their target price on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Sanford C. Bernstein initiated coverage on shares of Neurocrine Biosciences in a research report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 target price for the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Tuesday, April 21st. Piper Sandler raised their target price on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, BMO Capital Markets decreased their price target on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $186.05.

Insider Transactions at Neurocrine Biosciences

In other news, insider Jude Onyia sold 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $155.53, for a total value of $1,710,830.00. Following the transaction, the insider owned 25,846 shares in the company, valued at approximately $4,019,828.38. This represents a 29.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the completion of the transaction, the director owned 511,293 shares in the company, valued at approximately $78,907,848.69. This represents a 32.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 278,786 shares of company stock valued at $43,099,615. 4.60% of the stock is currently owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.